Anderson, W.F., “Human Gene Therapy,” Nature 392:25-30 (1998). |
Bennett, C.F., “Antisense Oligonucleotides: Is the Glass Half Full or Half Empty?,” Biochem. Pharmacol. 55:9-19 (1998). |
Blomer, et al., “Bcl-xL protects adult septal cholinergic neurons from axotomized cell death,” Proc. Natl. Acad. Sci. USA 95:2603-2608 (1998). |
Branch, A.D., “A good antisense molecule is hard to find,” TIBS 23:45-50 (1998). |
Buchschacher, et al., “Human Immunodeficiency Virus Vectors for Inducible Expression of Foreign Genes,” J. Virology 66(5):2731-2739 (1992). |
Bukrinsky, et al., “A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells,” Nature 365:666-669 (1993). |
Burns, et al., “vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells,” Proc. Natl. Acad. Sci. USA 90:8033-8037 (1993). |
Carroll, et al., “A Human Immunodeficiency Virus Type 1 (HIV-1)-Based Retroviral Vector System Utilizing Stable HIV-1 Packaging Cell Lines,” J. Virology 68(9):6047-6051 (1994). |
Cohen, J., “New Role for HIV: A Vehicle For Moving Genes Into Cells,” Science 272:195 (1996). |
Crooke, S.T., “An Overview of Progress in Antisense Therapeutics” Antisense & Nucl. Acid Drug Devel. 8:115-122 (1998). |
Dalgleish, et al., “Neutralization of Diverse HIV-1 Strains by Monoclonal Antibodies Raised against a gp41 Synthetic Peptide,” Virology 165:209-215 (1988). |
Deminie, et al., “Functional Exchange of an Oncoretrovirus and a Lentivirus Matrix Protein,” J. Virology 68(7):4442-4449 (1994). |
Fahraeus, et al., “New Approaches to Cancer Therapies,” J. Pathology 187:138-146 (1999). |
Farnet, et al., Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules, Proc. Natl. Acad. Sci. USA 93:9742-9747 (1996). |
Farnet, et al., “HIV-1 cDNA Integration: Requirement of HMG l(Y) Protein for Function of Preintegration Complexes in Vitro,” Cell 88:483-492 (1997). |
Farnet, et al., “Human Immunodeficiency Virus Type 1 cDNA Integration: New Aromatic Hydroxylated Inhibitors and Studies of the Inhibition Mechanism,” Antimicrob. Agents and Chemo. 42(9):2245-2253 (No Month, Year). |
Gallay, et al., “HIV-1 Infection of Nondividing Cells: C-Terminal Tyrosine Phosphorylation of the Viral Matrix Protein Is a Key Regulator,” Cell 80:379-388 (1995). |
Goldman, et al., “Lentiviral Vectors for Gene Therapy of Cystic Fibrosis,” Human Gene Therapy 8:2261-2268 (1997). |
Gura, T., “Antisense Has Growing Pains,” Science 270:575-577 (1995). |
Hansen, et al., “Human Immunodeficiency Virus Type 2 Preintegration Complexes: Activities In Vitro and Response to Inhibitors,” J. Virology 71(4):3351-3356 (No Month, Year). |
Heinzinger, et al., “The V pr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells,” Proc. Natl. Acad. Sci. USA 91:7311-7315 (1994). |
Kay, et al., “Gene Therapy,” Proc. Natl. Sci. USA 94:12744-12746 (1997). |
Kim, et al., “A Short Sequence Upstream of the 5′ Major Splice Site Is Important for Encapsidation of HIV-1 Genomic RNA,” Virology 198:336-340 (1994). |
Landau, et al., “Pseudotyping with Human T-Cell Leukemia Virus Type I Broadens the Human Immunodeficiency virus Host Range,” J. Virology 65(1):162-169 (1991). |
Ledley, F.D., “Clinical Considerations in the Design of Protocols for Somatic Gene Therapy,” Human Gene Therapy 2:77-83 (1991). |
Lewis, et al., “Human immunodeficiency virus infection of cells arrested in the cell cycle,” The EMBO J. 11(8):3053-3058 (1992). |
Lusso, et al., “Expanded HIV-1 Cellular Tropism by Phenotypic Mixing with Murine Endogenous Retroviruses,” Science 247:848-852 (1990). |
Mastrangelo, et al., “Gene Therapy for Human Cancer: An Essay for Clinicians,” Seminars in Oncology 23(1):4-21 (1996). |
Miller, et al., “Human Immunodificiency Virus Type 1 Preintegration Complexes: Studies of Organization and Composition,” J. Virology 71(7):5382-5390 (1997). |
Naldini, et al., “In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector,” Science 272:263-267 (1996). |
Page, et al., “Construction and Use of a Human Immunodeficiency Virus Vector for Analysis of Virus Infectivity,” J. Virology 64(11):5270-5276 (1990). |
Poznansky, et al., “Gene Transfer into Human Lymphocytes by a Defective Human Immunodeficiency Virus Type 1 Vector,” J. Virology 65(1):532-536 (1991). |
Richardson, et al., “Helper virus-free transfer of human immunodeficiency virus type 1 vectors,” J. Gen. Virology 76:691-696 (1995). |
Schwedler, et al., “The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes,” Proc. Natl. Acad. Sci. USA 91:6992-6996 (1994). |
Touchette, N., “Gene therapy: Not ready for prime time,” Nature Medicine 2(1):7-8 (1996). |
Trono, et al., “HIV-1 Gag Mutants Can Dominantly Interfere with the Replication of the Wild-Type Virus,” Cell 59:113-120 (No Month Year). |
Verma, et al., “Gene therapy—promises, problems and prospects,” Nature 389:239-242 (1997). |
Farnet, et al., “Human immunodeficiency virus type 1 cDNA integration: new aromatic hydroxylated inhibitors and studies of the inhibition mechanism,” Antimicrobial Agents and Chemotherapy, vol. 42, No. 9, p. 2245-2253 (1998). |
Hansen and Bushman, “Human immunodeficiency virus type 2 preintegration complexes: activities in vitro and response to inhibitors,” Journal of Virology, vol. 71, No. 4, p. 3351-3356 (1997). |
Miller, et al., “Human innumodeficiency virus type 1 preintegration complexes: studies of organization and composition,” Journal of Virology, vol. 71, p. 5382-5390 (1997). |
Farnet and Bushman, “HIV-1 cDNA integration: requirement of HMG I(Y) protein for function of preintegration complexes in vitro,” Cell, vol. 86, pp. 483-492 (1997). |
Farnet, et al., “Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules,” Proc. Natl. Acad. Sci. USA, vol. 93, pp. 9742-9747 (1996). |
Naviaux, et al., “The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses,” Journal of Virology, p. 5701-5705 (1996). |
Yu, et al., “Inducible human immunodeficiency virus type 1 packaging cell lines,” Journal of Virology, p. 4530-4537 (1996). |
Farnet and Hazeltine, “Integration of human immunodeficiency virus type 1 DNA in vitro,” Proc. Natl. Acad. Sci. USA, vol. 87, pp. 4164-4168 (1990). |
Ellison, et al., “Human Immunodeficiency Virus Integration in a Cell-Free System,” Journal of Virology, vol. 64, p. 2711-2715 (1990). |